App-Quantinova.ai

Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis.

Funda Meric-Bernstam - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hyperphosphatemia

N/A

Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study.

Claudia A.M. Fulgenzi - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Systemic inflammation

Atezolizumab

Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results.

Shubham Pant - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

L-Tyrosine

A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).

T.R. Jeffry Evans - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Durvalumab

NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).

Mairead Geraldine McNamara - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High-grade extrapulmonary neuroendocrine carcinoma

Irinotecan

Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.

Thorvardur Ragnar Halfdanarson - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroenteropancreatic neuroendocrine carcinomas

Somatostatin

NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Zev A. Wainberg - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

5-fluorouracil + leucovorin

Tissue factor (TF) and factor VII/TF ratio (fVIIa:TF) as potential indicators of malignancy in pancreatic cystic lesions.

Farzana Haque - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Phase II study (daNIS-1) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).

Li-Yuan Bai - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

PDR001

The relationship between CT-derived sarcopenia, systemic inflammation, physical function and survival in patients with advanced cancer.

Josh McGovern - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Systemic inflammation

N/A

First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer.

Lorelei A Mucci - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Neoadjuvant platinum-based chemotherapy for clinically node-positive penile squamous cell carcinoma: An international, multicenter, real-world study.

Kyle M. Rose - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma

N/A

Differential expression of PDL-1 and tumour-associated macrophages in N0 and N+ penile cancer.

Fowz Azhar - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Penile carcinoma

N/A

Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

Noel W. Clarke - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Prednisolone

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Enzalutamide

Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.

Alan Haruo Bryce - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Rucaparib

Prostate cancer screening: Have we tipped the seesaw?

Matthew David Hobbs - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US).

Pedro C. Barata - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

N/A

Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US).

Pedro C. Barata - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

ribose

First UK experience of apalutamide in metastatic and non-metastatic prostate cancer outside of clinical trials.

Prantik Das - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Prostate cancer

Androgen Tear

Filters

45280 Abstracts